Paul Griffin

Professor Paul Griffin is an Associate Professor of Medicine at the University of Queensland Medical School and Director of Infectious Diseases at Mater Health Services. He leads clinical research at Nucleus Network, overseeing over 125 clinical trials, including 8 COVID-19 vaccines and malaria studies. His expertise spans infectious diseases, clinical microbiology, and vaccine development. He chairs the Advanced Training Committee in Infectious Diseases for the Royal Australasian College of Physicians and advises the Immunisation Coalition. Key roles include medical directorships, media advocacy during the pandemic, and leadership in diagnostic microbiology, particularly metagenomic sequencing applications.

• Education: Fellowship in Infectious Diseases (Royal Australasian College of Physicians), Clinical Microbiology (Royal College of Pathologists of Australasia), and Tropical Medicine (Australasian College of Tropical Medicine).

Research Interests: Focuses on vaccine development, antimicrobial resistance, malaria therapeutics, and public health strategies. His work integrates clinical trials, pathogen detection via metagenomics, and post-viral syndromes (e.g., Long COVID). Key projects include evaluating novel antimalarials, SARS-CoV-2 vaccine efficacy, and improving Clostridioides difficile infection management. His studies often bridge basic science and translational medicine.

Recent publications highlight advancements in antimalarial agents, quantum computing for vaccine analytics, and post-COVID ion channel dysfunction. He collaborates globally, including with organizations like Nucleus Network and the WHO.

Grants & Funding: Extensive grants supporting clinical trials, vaccine research, and tropical disease studies. Financial support includes industry partnerships (e.g., Novavax, Moderna) and government health initiatives.

Labs/Teams: Leads the Mater Clinical Unit’s Infectious Diseases team and collaborates with Nucleus Network’s clinical trial platforms. Engages in multidisciplinary groups for metagenomic diagnostics and vaccine efficacy evaluations.